Health Canada has given the green light to Neffy, a groundbreaking needle-free epinephrine nasal spray designed to treat severe allergic reactions — marking the first time Canadians will have a non-injection option for emergency allergy treatment.
The approval represents a significant shift in how people manage life-threatening allergic emergencies. ALK Canada, the company distributing the medication, confirms the two-milligram formulation is approved for adults and children weighing at least 30 kilograms (roughly 66 pounds), with the product expected to reach Canadian pharmacy shelves as early as this summer.
Why This Matters for Allergy Sufferers
Currently, epinephrine auto-injectors — commonly known as EpiPens — are the only emergency treatment available across Canada for severe allergic reactions. These single-use devices require users to inject medication directly into muscle tissue, a process that has historically created barriers for patients hesitant about needles.
Dr. Mariam Hanna, an adjunct clinical professor of pediatrics at McMaster University in Hamilton, explains the real-world impact:
"Some patients and even their parents have shown reluctance to use auto-injectors when needed. That delay during a life-threatening reaction is not good for outcomes," Hanna noted. "It's a big deal that Neffy removes the needle-related aspects. We're hoping people will be more ready to use it in emergencies rather than delaying."
Hanna emphasized that removing the psychological and physical barrier of needles could be transformative for allergy management. The non-needle delivery system addresses a genuine clinical concern — patient hesitation that can prove dangerous during anaphylactic emergencies.
A Pocket-Sized Alternative with Long Shelf Life
Neffy arrives as a compact, pocket-sized treatment with a 30-month shelf life from manufacture. The nasal spray format eliminates the complex deployment mechanics that some users find stressful, offering a simpler administration method during high-stress medical emergencies.
The United States approved Neffy in summer 2024 in both two-milligram and one-milligram doses. Canada's approval currently covers only the two-milligram formulation, though the lower dose may be considered for future approval.
Supply Security and Choice
The introduction of a second epinephrine treatment option carries practical benefits beyond patient preference. Food Allergy Canada, a Toronto-based advocacy organization, called the approval "an important step forward" that expands patient choices.
Dr. Hanna highlighted another critical advantage: supply resilience. In 2018, Canada experienced significant EpiPen supply disruptions that left many allergy sufferers vulnerable. Having multiple approved epinephrine treatments reduces the risk of similar shortages affecting emergency care access.
"It's great to have more than one option, and it's fabulous that the other option doesn't have a needle," Hanna concluded.
For Calgary and Alberta residents managing severe allergies, Neffy represents a meaningful advancement in emergency preparedness — one that could literally save lives by removing barriers to timely treatment during anaphylactic reactions.
This article is based on reporting from CBC Health.